Navigation Links
OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
Date:8/1/2013

NEW YORK, Aug. 1, 2013 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of Optimer Pharmaceuticals, Inc. ("Optimer" or the "Company") (NasdaqGS: OPTR) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Cubist Pharmaceuticals, Inc.

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

Click here to learn more about the investigation http://zlk.9nl.com/optimer-pharmaceuticals-optr/, or call: 877-363-5972.

Under the terms of the transaction, Optimer shareholders will receive $10.75 in cash for each share of Optimer stock they own. Optimer shareholders will also receive a Contingent Value Right entitling them to receive up to $5.00 for each share they own if certain net sales of the drug DIFICID are achieved. The investigation concerns whether the Optimer Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Cubist Pharmaceuticals, Inc. is underpaying for Optimer shares. In particular, at least one analyst set a price target of $25.00 per Optimer share.

If you own common stock in Optimer and wish to obtain additional information or discuss your rights, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/optimer-pharmaceuticals-optr/.  

Levi & Korsinsky is a national firm with offices in New York, New Jersey and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: 
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


'/>"/>
SOURCE Levi & Korsinsky, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
5. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
6. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
7. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
9. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
11. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... Sept. 12, 2017   EcoVadis , the leading platform for environmental, ... first annual edition of its Global CSR Risk and Performance Index. The ... EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points across ... ... ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... SignatureCare Emergency Center ... The $1000 student scholarship is awarded each semester to a deserving student. Congratulations ... who is a medical student at Arizona State University with a 3.63 GPA. ...
(Date:9/25/2017)... ... September 25, 2017 , ... The Coleman Institute, a ... an affiliate in Minneapolis-St. Paul, MN, Dr. Adam Locketz. Dr. Locketz will be ... aftercare planning through his Timewise Medical practice in the twin cities. , ...
(Date:9/25/2017)... ... 25, 2017 , ... SyncDog, Inc., the leading ... 3.0, will be available in a managed cloud services model, available from its ... several new enhancements including support for caller ID and network sharing for remote ...
(Date:9/25/2017)... ... 25, 2017 , ... FDAnews Expert Insight Series:, Device Regulation ... – 3:00 p.m. ET, http://www.fdanews.com/deviceregulation      , FDA Commissioner Scott ... short months:, ,     The first device recall over cybersecurity (a ...
(Date:9/25/2017)... SC (PRWEB) , ... September 25, 2017 , ... The ... efforts in helping those with disabilities. Each year the award is given to those ... people with disabilities live their best lives in communities of their choosing. Recent recipients ...
Breaking Medicine News(10 mins):